Donor CSF3R with the rs3917980A/G or G/G genotype is correlated with
better leukemia-free survival after allogenic hematopoietic stem cell
transplantation
Abstract
Polymorphisms in the granulocyte colony-stimulating factor receptor gene
(GCSFR, CSF3R) have been reported to be associated with peripheral blood
stem cell enrichment and hematological diseases. The aim of our study
was to investigate the effects of donor CSF3R allelic polymorphisms on
the outcomes of allogeneic stem cell transplantation. A total of 273
patients who were diagnosed with hematological diseases and treated with
allogeneic hematopoietic stem cell transplantation(allo-HSCT) were
enrolled in this study. Single-nucleotide polymorphisms in CSF3R were
genotyped by targeted next-generation sequencing. There were six types
of CSF3R genotypes with percentages over 1%. LFS and OS analyses showed
that recipients receiving grafts from healthy donors with an rs3917980
G/G or A/G genotype had higher LFS rates than those receiving grafts
from donors carrying an rs22754272 T/C genotype and the double negative
group (p=.036) Univariate analysis showed that donor CSF3R with the
rs2275472 T/C genotype was associated with higher
transplantation-related mortality(TRM) rates (HR=3.77, 95% CI:
1.416-9.631, p=.004) and higher rates of leukemia-free survival(LFS)
(HR=2.523; 95% CI: 1.032-6.13, p=.026). In addition, donor CSF3R with
the rs3917980G/G or A/G genotype was associated with better overall
survival(OS) rates (HR=0.512, 95% CI: 0.244-1.017, p=.047). Our
findings demonstrate the important prognostic value of genetic
variations in donor CSF3R to predict clinical outcomes in patients
undergoing allo-HSCT.